Literature DB >> 1424782

Mononuclear phagocytes as targets, tissue reservoirs, and immunoregulatory cells in human immunodeficiency virus disease.

M S Meltzer1, H E Gendelman.   

Abstract

We have presented evidence in this review for the following: 1. Macrophages are likely the first cell infected by HIV. Studies document recovery of HIV into macrophages in the early stages of infection in which virus isolation in T cells is unsuccessful and detectable levels of antibodies against HIV are absent. 2. Macrophages are major tissue reservoirs for HIV during all stages of infection. Unlike the lytic infection of T cells, many HIV-infected macrophages show little or no virus-induced cytopathic effects. HIV-infected macrophages persist in tissue for extended periods of time (months) with large numbers of infectious particles contained within intracytoplasmic vacuoles. 3. Macrophages are a vector for the spread of infection to different tissues within the patient and between individuals. Several studies suggest a "Trojan horse" role for HIV-infected macrophages in dissemination of infectious particles. The predominant cell in most bodily fluids (alveolar fluid, colostrum, semen, vaginal secretions) is the macrophage. In semen, for example, the numbers of macrophages exceed those of lymphocytes by more than 20-fold (Wolf and Anderson 1988). 4. Macrophages are major regulatory cells that control the pace and intensity of disease progression in HIV infection. Macrophage secretory products are implicated in the pathogenesis of CNS disease and in control of viral latency in HIV-infected T cells. This litany of events in which macrophages participate in HIV infection in man parallels similar observations in such animal lentivirus infections as visna-maedi or caprine arthritis-encephalitis viruses. HIV interacts with monocytes differently than with T cells. Understanding this interaction may more clearly define both the pathogenesis of HIV disease and strategies for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424782     DOI: 10.1007/978-3-642-77377-8_9

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  26 in total

1.  Interaction of human immunodeficiency virus type 2 Vpx and invariant chain.

Authors:  H A Pancio; N Vander Heyden; K Kosuri; P Cresswell; L Ratner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

3.  Macrophage endocytic trafficking of antiretroviral nanoparticles.

Authors:  Irena Kadiu; Ari Nowacek; Joellyn McMillan; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2011-03-21       Impact factor: 5.307

Review 4.  The macrophage response to HIV-1: Intracellular control of X4 virus replication accompanied by activation of chemokine and cytokine synthesis.

Authors:  Iqbal H Chowdhury; Galina Bentsman; Wonkyu Choe; Mary Jane Potash; David J Volsky
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

5.  Permanent occupancy of the human immunodeficiency virus type 1 enhancer by NF-kappa B is needed for persistent viral replication in monocytes.

Authors:  J M Jacqué; B Fernández; F Arenzana-Seisdedos; D Thomas; F Baleux; J L Virelizier; F Bachelerie
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  HIV-1 transforms the monocyte plasma membrane proteome.

Authors:  Irena Kadiu; Tong Wang; Joshua D Schlautman; Larisa Dubrovsky; Pawel Ciborowski; Michael Bukrinsky; Howard E Gendelman
Journal:  Cell Immunol       Date:  2009-04-08       Impact factor: 4.868

7.  Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice.

Authors:  Enrico Garaci; Stefano Aquaro; Caterina Lapenta; Alessandra Amendola; Massimo Spada; Sonia Covaceuszach; Carlo-Federico Perno; Filippo Belardelli
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

Review 8.  NanoART, neuroAIDS and CNS drug delivery.

Authors:  Ari Nowacek; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

Review 9.  Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies.

Authors:  Benson J Edagwa; Tian Zhou; JoEllyn M McMillan; Xin-Ming Liu; Howard E Gendelman
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

10.  5α-reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 Tat.

Authors:  Jason J Paris; ShiPing Zou; Yun K Hahn; Pamela E Knapp; Kurt F Hauser
Journal:  Brain Behav Immun       Date:  2016-01-13       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.